ReviewCurrent hypertension reports2014
New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases.
Review in Current hypertension reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Investigation onPharmaceuticals (Basel, Switzerland) · 2026Article
- Differential methylation in blood pressure control genes is associated to essential hypertension in African Brazilian populations.Epigenetics · 2025Article
- Unveiling the Carbonic Anhydrase Inhibitory Profile of Aprocitentan: Kinetic and Structural Characterization.ACS medicinal chemistry letters · 2025Article
- Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors inPharmaceuticals (Basel, Switzerland) · 2025Article
- Altitude illnesses.Nature reviews. Disease primers · 2024Review
- Carbonic anhydrase, its inhibitors and vascular function.Frontiers in molecular biosciences · 2024Review
- Thiazides in chronic kidney disease: "back to the future".Clinical kidney journal · 2023Article
- Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited.Fluids and barriers of the CNS · 2022Review
- Carbonic anhydrase IX and hypoxia-inducible factor 1 attenuate cardiac dysfunction after myocardial infarction.Pflugers Archiv : European journal of physiology · 2021Article
- Molecular mechanisms of brain water transport.Nature reviews. Neuroscience · 2021Review
- Thiazide and other Cl-benzenesulfonamide-bearing clinical drug affinities for human carbonic anhydrases.PloS one · 2021Article
- Carbonic anhydrase II does not regulate nitrite-dependent nitric oxide formation and vasodilation.British journal of pharmacology · 2020Article
- Network Pharmacology-Based Analysis of the Pharmacological Mechanisms of Aloperine on Cardiovascular Disease.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Increased Levels of cAMP by the Calcium-Dependent Activation of Soluble Adenylyl Cyclase inCells · 2019Article
- Review
- Mechanism of Thiazide Diuretic Arterial Pressure Reduction: The Search Continues.Frontiers in pharmacology · 2019Review
- Systemic Hypertension at High Altitude.Hypertension (Dallas, Tex. : 1979) · 2018Review
- Acetazolamide and Cardiac Failure.Clinical drug investigation · 2018Article
- Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.MedChemComm · 2017Article
- Bioactive Natural Product and Superacid Chemistry for Lead Compound Identification: A Case Study of Selective hCA III and L-Type CaMolecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbonic anhydrase (CA) and its inhibitors are relevant to many physiological processes and diseases. The enzyme is differentially expressed throughout the body, in concentration and subcellular location, and as 13 catalytically active isoforms. Blood vessels contain small amounts of CA, but the enzyme's role in vascular physiology and blood pressure regulation is uncertain. However, considerable recent evidence points to vasodilation by CA inhibitors. CA inhibition in vascular smooth muscle, endothelium, heart, blood cells, and nervous system could all contribute. It is equally plausible that other targets besides CA for all known CA inhibitors may account for their vascular effects. I will review this knowledge and important remaining gaps relating to treatment of hypertensive-related diseases with potent sulfonamide inhibitors, such as acetazolamide; but also the possibility that CA inhibition by thiazides and loop diuretics, although generally weaker, may have antihypertensive effects beyond their inhibition of renal sodium transporters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.